[
  {
    "ts": null,
    "headline": "MRNA Q1 Earnings Call: Management Focuses on Cost Reductions and Pipeline Progress Amid Revenue Shortfall",
    "summary": "Biotechnology company Moderna (NASDAQ:MRNA) missed Wall Street’s revenue expectations in Q1 CY2025, with sales falling 35.3% year on year to $108 million. The company’s full-year revenue guidance of $2 billion at the midpoint came in 6.1% below analysts’ estimates. Its non-GAAP loss of $2.22 per share was 28.6% above analysts’ consensus estimates.",
    "url": "https://finnhub.io/api/news?id=bab42e76712afc3ecb9515c41820c2c2d3ffbc935229b97a36618d7a12e65c21",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747261457,
      "headline": "MRNA Q1 Earnings Call: Management Focuses on Cost Reductions and Pipeline Progress Amid Revenue Shortfall",
      "id": 134465995,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRNA",
      "source": "Yahoo",
      "summary": "Biotechnology company Moderna (NASDAQ:MRNA) missed Wall Street’s revenue expectations in Q1 CY2025, with sales falling 35.3% year on year to $108 million. The company’s full-year revenue guidance of $2 billion at the midpoint came in 6.1% below analysts’ estimates. Its non-GAAP loss of $2.22 per share was 28.6% above analysts’ consensus estimates.",
      "url": "https://finnhub.io/api/news?id=bab42e76712afc3ecb9515c41820c2c2d3ffbc935229b97a36618d7a12e65c21"
    }
  },
  {
    "ts": null,
    "headline": "Q1 Therapeutics Earnings: United Therapeutics (NASDAQ:UTHR) Impresses",
    "summary": "As the Q1 earnings season wraps, let’s dig into this quarter’s best and worst performers in the therapeutics industry, including United Therapeutics (NASDAQ:UTHR) and its peers.",
    "url": "https://finnhub.io/api/news?id=5d1b4933b8f2f350013fdcdf5234ad467178f93a9f926311b7b168c431989ec6",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747193465,
      "headline": "Q1 Therapeutics Earnings: United Therapeutics (NASDAQ:UTHR) Impresses",
      "id": 134460789,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRNA",
      "source": "Yahoo",
      "summary": "As the Q1 earnings season wraps, let’s dig into this quarter’s best and worst performers in the therapeutics industry, including United Therapeutics (NASDAQ:UTHR) and its peers.",
      "url": "https://finnhub.io/api/news?id=5d1b4933b8f2f350013fdcdf5234ad467178f93a9f926311b7b168c431989ec6"
    }
  },
  {
    "ts": null,
    "headline": "Moderna, Inc. (MRNA): Among the Best Growth Stocks to Buy and Hold for the Long Term",
    "summary": "We recently compiled a list of the 12 Best Growth Stocks to Buy and Hold for the Long Term. In this article, we are going to take a look at where Moderna, Inc. (NASDAQ:MRNA) stands against the other growth stocks. What’s the Bull Case for US Equities? The market closed last week mostly lower, however, the […]",
    "url": "https://finnhub.io/api/news?id=93e24b49703bb94fa33f1a9240048545f498be117ffe991ecda1419c762a93ad",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747188486,
      "headline": "Moderna, Inc. (MRNA): Among the Best Growth Stocks to Buy and Hold for the Long Term",
      "id": 134461720,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRNA",
      "source": "Yahoo",
      "summary": "We recently compiled a list of the 12 Best Growth Stocks to Buy and Hold for the Long Term. In this article, we are going to take a look at where Moderna, Inc. (NASDAQ:MRNA) stands against the other growth stocks. What’s the Bull Case for US Equities? The market closed last week mostly lower, however, the […]",
      "url": "https://finnhub.io/api/news?id=93e24b49703bb94fa33f1a9240048545f498be117ffe991ecda1419c762a93ad"
    }
  }
]